Male Breast Cancer Completed Phase 2 Trials for Capecitabine (DB01101)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00068588GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast CancerTreatment